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Abstract 
Background: Models of human glucose-insulin physiology have been developed for a range of uses, 
with similarly different levels of complexity and accuracy. STAR (Stochastic Targeted) is a model-
based approach to glycaemic control. Elevated blood glucose concentrations (hyperglycaemia) are a 
common complication of stress and prematurity in very premature infants, and have been associated 
with worsened outcomes and higher mortality. This research identifies and validates the model 
parameters for model-based glycaemic control in neonatal intensive care. 
Methods: C-peptide, plasma insulin, and BG from a cohort of 41 extremely pre-term (median age 
27.2 [26.2 - 28.7] weeks) and very low birth weight infants (median birth weight 839 [735 – 1000] g) 
are used alongside C-peptide kinetic models to identify model parameters associated with insulin 
kinetics in the NICING (neonatal intensive care insulin-nutrition-glucose) model. A literature analysis 
is used to determine models of kidney clearance and body fluid compartment volumes. The full, final 
NICING model is validated by fitting the model to a cohort of 160 glucose, insulin, and nutrition data 
records from extremely premature infants from two different NICUs (neonatal intensive care units).  
Results: 6 Model parameters related to insulin kinetics were identified. The resulting NICING model 
is more physiologically descriptive than prior model iterations, including clearance pathways of 
insulin via the liver and kidney, rather than a lumped parameter. In addition, insulin diffusion between 
plasma and interstitial spaces is evaluated, with differences in distribution volume taken into 
consideration for each of these spaces. The NICING model was shown to fit clinical data well, with a 
low model fit error similar to that of previous model iterations.  
Conclusions: Insulin kinetic parameters have been identified, and the NICING model is presented for 
glycaemic control neonatal intensive care. The resulting NICING model is more complex and 
physiologically relevant, with no loss in bedside-identifiability or ability to capture and predict 
metabolic dynamics. 
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Introduction 
Mathematical models of glucose-insulin physiology have been developed with differing levels of 
complexity for a wide range of scientific and clinical applications. Models developed for the 
determination of model-based measures of physiology (e.g. [1, 2]), such as insulin sensitivity, tend to 
be more complex and comprehensive, requiring higher data density and/or measurement of multiple 
metabolic species. Other models are designed for specific clinical applications, such as glycaemic 
control in intensive care (e.g. [3-6]), or Type 1 Diabetes cohorts (e.g.[7]). These models tend to be 
less complex, as metabolic measurements are minimised in clinical or outpatient settings due to 
clinical and patient factors such as cost, availability, or comfort. In general, physiological models 
must have appropriate resolution, be mathematically identifiable [8], as well as practically applicable 
within their chosen application [9].  
While glucose-insulin models for adult intensive care applications are more widely documented [9, 
10] virtually no work has looked at neonatal intensive care unit (NICU) applications. Elevated blood 
glucose levels (BG) (Hyperglycaemia) is a common complication of prematurity and stress in 
neonatal intensive care, and while definitions and thresholds vary [11], studies show that 30-70% of 
very/extremely low birth weight infants have at least one BG> 8 mmol/L [12-16]. Hyperglycaemia is 
associated with increased mortality [15-17], and morbidity/complications in this cohort [15-21], but 
there is still debate over whether hyperglycaemia causes increased morbidity, or is reflective of 
worsened condition. 
There is no best practice method for the treatment of hyperglycaemia in this cohort. Use of insulin has 
been shown to increase glucose tolerance [22-27], resulting in increased weight gain [23, 25, 27], but 
also commonly results in increased incidence of hypoglycaemia (low blood glucose concentration) 
[28-30], which is also dangerous. In adult intensive care even a single hypoglycaemic episode has 
been associated with increased risk of mortality [31-33], while in neonatal intensive care 
hypoglycaemia as been associated with adverse neurological outcomes [34, 35]. Model-based 
methods for glycaemic control have been little investigated, due in part to the extremely fragile nature 
of this cohort and the subsequent limitations on invasive procedures and blood sample collection [36] 
that thus also limit the ability to identify parameters to validate more physiologically relevant and 
complex models. 
The aim of this study is twofold. First, this paper presents a clinically applicable and physiologically 
relevant model of glucose-insulin physiology in hyperglycaemic very/extremely premature infants 
(gestational age <32 weeks), and secondly it aims to identify insulin kinetic parameters for this model. 
With regards to the first aim, it combines a previous, simpler, model iteration in this cohort [37] with 
a more physiologically descriptive model currently utilised for glycaemic control in the adult 
intensive care unit [5]. Specifically, this model is more descriptive with regards to modelled insulin 
kinetics and dynamics [38], necessary for safe and effective glycaemic control.  
Related to the second aim, this paper also focuses on parameter identification of modelled insulin 
kinetics. While the key glucose dynamics have been previously published [39, 40], this study uses a 
previously published methodology from adults [41] and a novel data set of C-peptide concentrations 
from a very low birth weight (<1500g) cohort to evaluate diffusion of insulin between plasma and the 
interstitial fluid, and total liver and kidney clearance of insulin. In addition, the assumptions around 
insulin distribution volumes in the plasma and interstitial compartments are examined, and kidney 
glomerular filtration rate (GFR) is used to provide a patient specific value for renal clearance of 
insulin. The revised kinetics model is then used to create a new more physiologically relevant and 
complex, yet equally identifiable, glucose-insulin model, which is validated using clinical data.  
  
2.0 Models and Methods 
2.1 NICING Model of Glucose-Insulin Physiology  
The NICING (Neonatal Intensive Care Insulin-Nutrition-Glucose) model for glycaemic control in 
very/extremely preterm neonates is developed from a previous NICU model [37] and the ICING 
(Intensive Care Insulin-Nutrition-Glucose) model for adult intensive care [5]. The values given, with 
the exception of those derived in this study, are predominantly derived from literature, and are 
originally presented and discussed in [37, 39].  
In the new NICING model, blood glucose (𝐺 ∈ ℝ ∶ 𝐺 ≥ 0), plasma (𝐼 ∈ ℝ ∶ 𝐼 ≥ 0) and peripheral 
(𝑄 ∈ ℝ ∶ 𝑄 ≥ 0) insulin kinetics are described: 
?̇? = −𝑝𝐺𝐺(𝑡) −  𝑆𝐼𝐺(𝑡)
𝑄(𝑡)
1 + 𝛼𝐺𝑄(𝑡)
  +
𝑃𝑒𝑥(𝑡) +  𝐸𝐺𝑃 ∗ 𝑚𝑏𝑜𝑑𝑦 − 𝐶𝑁𝑆 ∗ 𝑚𝑏𝑟𝑎𝑖𝑛
𝑉𝑔,𝑓𝑟𝑎𝑐(𝑡) ∗ 𝑚𝑏𝑜𝑑𝑦
 (1) 
𝐼̇ =  − 
𝑛𝐿𝐼(𝑡)
1 + 𝛼𝐼𝐼(𝑡)
− 𝑛𝐾𝐼(𝑡) − 𝑛𝐼(𝐼(𝑡) − 𝑄(𝑡)) + 
𝑢𝑒𝑥(𝑡)
𝑉𝑃 ∗ 𝑚𝑏𝑜𝑑𝑦
+ (1 − 𝑥𝐿)𝑢𝑒𝑛 (2) 
?̇? = 𝑛𝐼  
𝑉𝑃
𝑉𝑄
(𝐼(𝑡) − 𝑄(𝑡)) − 𝑛𝐶
𝑄(𝑡)
1 +  𝛼𝐺𝑄(𝑡)
 (3) 
Where 𝐺  has units of mmol/L/min, and 𝐼 and 𝑄 have units of mU/L/min. Clearance of glucose 
includes both insulin mediated and non-insulin mediated routes. Insulin mediated uptake is modulated 
by insulin sensitivity (𝑠𝐼 ∈  ℝ ∶  𝑠𝐼  ≥ 10
−7), while non-insulin mediated routes include a brain-mass 
(mbrain ~14% whole body mass, mbody) dependant [40] central nervous system uptake (CNS = 0.088 
mmol/kg/min), and a concentration dependant pathway capturing other glucose clearances such as 
from the kidney (𝑝𝐺  = 0.003 /min). As 𝑝𝐺   trades off mathematically with SI and cannot be directly 
measured in this cohort, the adult value of 0.003/min is assumed. Glucose enters the system via 
exogenous (𝑃𝑒𝑥) inputs (parenteral and enteral) and endogenous glucose production (EGP = 0.033 
mmol/kg/min) by the liver [39]. 𝑉𝑔,𝑓𝑟𝑎𝑐 is the volume of distribution of glucose in plasma in litres and 
is based on gestational age [37]. Saturation of insulin mediated glucose uptake in adults is modulated 
with a Michaelis-Menten function, characterised by the parameter 𝛼𝐺. For neonates no saturation has 
been observed [42], so this value is 𝛼𝐺 = 0.  
Liver clearance of insulin occurs in two main processes, a first pass hepatic clearance of 
endogenously secreted insulin (xL) and clearance of insulin from circulating blood (rate constant: nL). 
This hepatic clearance is a receptor-mediated process resulting in saturation of clearance at high 
insulin concentrations [43, 44], and so is modelled with a Michaelis-Menten function, characterised 
by the parameter 𝛼𝐼. Saturation of liver clearance and first pass hepatic clearance of insulin cannot be 
measured in premature infants, or indirectly determined in this analysis, so the adult value of 𝛼𝐼 =
0.0017 𝐿/𝑚𝑈 and xL = 0.67 are used [5, 45].  
Kidney clearance of insulin (rate constant: 𝑛𝐾) includes both glomerular filtration of insulin, and 
proximal tubal reabsorption. Insulin movement between the plasma and interstitial fluid, (rate 
constant: 𝑛𝐼) is likely diffusion based, as it is not reported to be saturated [46, 47]. Insulin degradation 
by cells (rate constant: 𝑛𝐶) is a complex, receptor-mediated process. Receptor bound insulin can either 
be released back into the extracellular fluid space or internalised by the cell [43]. As insulin-binding 
and insulin-receptor mediated glucose uptake are related, both share the saturation parameter 𝛼𝐺 = 0. 
Insulin is secreted (uen) or is exogenously delivered (uex), with units of mU/min. Insulin secretion can 
be calculated using C-peptide [48, 49], a molecule secreted in equimolar quantities to insulin with 
simpler clearance kinetics. If C-Peptide measurements are not available, insulin secretion is modelled 
[49, 50]: 
𝑢𝑒𝑛 =  {
max(4.2, −1.5 + 1.9 ∗ 𝐺)   
max(2.2, −0.37 + 0.86 ∗ 𝐺)
 
     if female
  if male
 (4) 
The volume of distribution of plasma insulin is assumed to be the blood plasma volume (VP). The 
volume of distribution of insulin in the peripheral compartment is approximated as the interstitial fluid 
volume (VQ).  
 
 
2.2 C-peptide Kinetic Model 
C-peptide is a protein secreted in equimolar quantities with insulin. However, unlike insulin, it is only 
cleared by the kidney. Therefore, the relatively simple kinetics of C-peptide provide a means to 
estimate insulin secretion. The well known 2 compartment kinetics model [48] is used due to its 
overall physiological relevance: 
𝑑?̂?
𝑑𝑡
= ?̂? − (𝑘1 + 𝑘3)?̂? + 𝑘2?̂? (5) 
𝑑?̂?
𝑑𝑡
= 𝑘1?̂? − 𝑘2?̂? (6) 
Where ?̂? (?̂? ∈ ℝ ∶ ?̂? ≥ 0 [pmol]) is the amount of C-peptide in the central compartment of plasma 
(and tissues in rapid equilibrium with the plasma), and ?̂? (?̂? ∈ ℝ ∶ ?̂? ≥ 0 [pmol]) is the amount of C-
peptide in the peripheral extra vascular compartment. ?̂? is the rate at which C-peptide, and thus 
insulin, is secreted into the central compartment [pmol/min]. Assuming the same diffusive properties 
between compartments gives 𝑘2 =  𝑘1(𝑉𝑃 𝑉𝑄⁄ ), and considering the concentrations of C-peptide in 
central and peripheral compartments (𝐶, 𝑌 ∈ ℝ ∶ 𝐶, 𝑌 ≥ 0 ) with units [pmol/L], allows the model to 
be rewritten: 
𝑑𝐶
𝑑𝑡
= 𝑆 − 𝑛𝐼𝑐𝑝(𝐶 − 𝑌) − 𝑛𝑘𝑐𝑝𝐶 (7) 
𝑑𝑌
𝑑𝑡
= 𝑛𝐼𝑐𝑝
𝑉𝑃
𝑉𝑄
(𝐶 − 𝑌) (8) 
Where: 
𝑛𝐼𝑐𝑝 =  𝑘1  (9) 
𝑛𝑘𝑐𝑝 =  𝑘3 (10) 
The rate parameter 𝑛𝐼𝑐𝑝 describes the rate of transport of C-peptide from the central to the peripheral 
compartment, and vice versa, and assumes that 𝑘2 =  𝑘1(𝑉𝑃 𝑉𝑄⁄ ),  in the model presented in [48]. The 
parameter 𝑛𝑘𝑐𝑝 describes irreversible removal of C-peptide from central compartment via the kidney. 
Rate parameters in Equation 9 are renamed to allow consistency with the NICING model structure, 
and reflect the assumption that the rates of forward and reverse diffusion between compartments are 
equal.    
Since no studies have been performed in preterm or term neonates to determine the C-peptide 
kinetics, adult data and methodology [48, 51] was used as a reasonable approximation since the 
kinetic compartments and their functional physiology are the same. The values for these parameters 
are given in Table 1, and were adapted to this cohort using the methods in [48] and an age of 0 years, 
according to the equation: 
𝑙𝑜𝑛𝑔 ℎ𝑎𝑙𝑓 𝑙𝑖𝑓𝑒 (𝑚𝑖𝑛) =  0.14 ∗ 𝑎𝑔𝑒 (𝑦𝑒𝑎𝑟𝑠) +  29 (11) 
𝑘2 =  𝐹 (𝑏 − 𝑎) +  𝑎 (12) 
𝑘3 =  
𝑎 𝑏
𝑘2
 (13) 
𝑘1 =  𝑎 +  𝑏 − 𝑘2 −  𝑘3 (14) 
where a = log(2)/(short half life), and b = log(2)/(long half life). This age-based extrapolation from 
adult data does not utilise the model within the limits of the cohort it was originally validated in. This 
extrapolation was necessary, as C-peptide kinetic data is not available for the premature neonate. 
However, all parameters fall within the adult ranges (Van Cauter et al., 1992, Polonsky et al., 1986) 
and were these parameters to scale differently in neonates, it would simply offset SI without changing 
underlying dynamics. As such, these values within the adult range are considered a justifiable 
estimation of neonatal behaviour. 
Table 1: C-peptide model parameter values 
Parameter Value [1/min] 
k1 0.0478 
k2 0.0516 
k3 0.0644 
 
Sampling constraints due to limited blood volume in this cohort meant frequent, serial measurements 
of C-peptide were not possible. Assuming steady state conditions, it follows from Equation 8 that the 
rate of C-peptide entering and leaving the peripheral compartment must be equal. Hence, substituting 
this equality into Equation 5 and rearranging yields:  
𝑆 =  𝑛𝑘𝑐𝑝𝐶 =  𝑘3𝐶 (15) 
Since insulin is secreted in equimolar quantities alongside C-peptide, then under steady state 
conditions the rate of secretion of insulin, uen, can be estimated from the rate of excretion of C-peptide 
from the central compartment.  
2.3 Insulin Kinetic Parameter Identification 
2.3.1 Insulin Clearance Parameters 
Insulin clearance kinetics were determined using the model-based method of [41], which used C-
peptide kinetics in combination with the ICING model and patient data to determine appropriate 
insulin clearance parameter values. The diffusion constant for insulin between the plasma and 
interstitial compartments is modelled as the C-peptide transfer rate scaled by molar mass [41]: 
𝑛𝐼 =  𝑛𝐼𝐶𝑃
𝑚𝑐
𝑚𝐼
= 𝑘1
𝑚𝑐
𝑚𝐼
 (16) 
Where 𝑚𝑐 = 3.02𝑘𝐷𝑎 and 𝑚𝐼 = 5.8𝑘𝐷𝑎 are the molecular masses of C-Peptide and Insulin, 
respectively. Diffusion can be complex to characterise, so sensitivity to this parameter was tested by 
multiplying the mass ratio by powers of 1/3 to 1/1, with the former power based on Einstein’s theory 
for diffusion of molecules in solution [52]. 
To determine 𝑛𝐶, steady state is assumed and Equation 3 re-arranged to yield: 
𝑛𝐶 =  𝑛𝐼
𝑉𝑃
𝑉𝑄
(
𝐼𝑠𝑠
𝑄𝑠𝑠
− 1) (17) 
In adults, studies indicate that the steady state interstitial to plasma insulin ratio (Qss/Iss) is between 0.4 
and 0.6 [53-56]. In this study, a ratio of 0.5 is used. 
If steady state conditions are also applied to Equation 2 then the sum of the kidney and liver 
clearances can be estimated: 
𝑛𝐾 + 𝑛𝐿 ≈  
−𝑛𝐼(𝐼𝑠𝑠 − 𝑄𝑠𝑠) + 
𝑢𝑒𝑥(𝑡)
𝑉𝑃 ∗ 𝑚𝑏𝑜𝑑𝑦
+ (1 − 𝑥𝐿)𝑢𝑒𝑛
𝐼𝑠𝑠
 
(18) 
2.3.2 Kidney Clearance of Insulin 
It is estimated that 30-80% of insulin in the systemic circulation is removed by the kidneys [57]. 
Renal clearance of insulin occurs via two pathways: glomerular filtration, and absorption from the 
peritubular capillaries. Glomerular filtration compromises about 60% of total insulin clearance by the 
kidney [57]. Creatinine and inulin clearance are two common molecules used to estimate glomerular 
filtration rate (GFR). The rate of glomerular filtration of insulin is approximately 90% that of inulin 
determined GFR [58].  As such, total insulin clearance via the kidney can be estimated: 
𝑛𝑘 =  
1
𝑉𝑃
×
0.9 𝐺𝐹𝑅𝑖𝑛𝑢𝑙𝑖𝑛
0.6 
 (19) 
Where 𝐺𝐹𝑅𝑖𝑛𝑢𝑙𝑖𝑛 is in units of ml/min, and 𝑉𝑃 is the distribution volume of insulin. For this cohort, 
𝐺𝐹𝑅𝑖𝑛𝑢𝑙𝑖𝑛can be estimated using [59]: 
𝐺𝐹𝑅𝑖𝑛𝑢𝑙𝑖𝑛 = 0.45 + 0.24𝑚𝑏𝑤 + 0.18𝐴𝑃𝑁  (20) 
Here 𝑚𝑏𝑤  is the birth is weight, and 𝐴𝑃𝑁 is the postnatal age in weeks. 
2.3.3 Insulin Volumes of Distribution 
Previously it was indirectly assumed that interstitial and blood plasma fluid volumes of distribution 
for insulin were essentially equal [37]. This assumption is not correct for neonates, and a literature 
search in PubMed was carried out to determine how plasma and interstitial fluid volumes change over 
time or between patients. As interstitial fluid volume is the extracellular fluid volume (ECV) minus 
the plasma volume (VP), extracellular fluid volumes were also included in the search. Key search 
terms included: plasma, extracellular, interstitial, fluid volume, and neonate. Exclusion criteria 
included lack of reported values, non-human or adult fluid volumes reported. Fluid volumes were 
analysed in units of mL/kg. Results were plotted against postnatal age and reported standard 
deviations were included as error bars. 
2.4 Clinical Data and Model Validation 
2.4.1 C-peptide Data 
The clinical data used here has been described in detail elsewhere [49, 50]. In summary, three to four 
blood samples were taken from 88 hyperglycaemic (two BG measures >8.5 mmol/L more than 4 
hours apart) very preterm (born at <32 weeks gestation) and/or very low birth weight (<1500g) infants 
enrolled in a randomised trial of glycaemic control (the HINT trial [28], Auckland, New Zealand). 
Blood samples were taken at randomisation (0-5 days post natal age) and at approximately 7, 14 and 
21 days after randomisation.   
Plasma insulin (Azsym system auto-analyzer, Abbott Laboratories, Abbott Park, IL)  and glucose 
(glucose oxidise method, ABL 700, Radiometer Ltd, Copenhagen, Denmark) concentrations were 
determined as part of the study, and remaining blood from the samples was frozen. Of the original 
cohort of 88, 41 were of GA<32 weeks and had 1 or more samples with sufficient remaining blood 
volume available for retrospective C-peptide analysis. C-peptide concentrations were determined 
using immunometric assays (Elecsys 2010, Roche Diagnostics, Germany). Table 2 provides 
demographic data over the sample cohort, as well raw sample results. 
2.4.2 Model Validation Cohorts 
The model was validated through retrospective fitting to clinically charted glycaemic data from two 
New Zealand NICU cohorts. The Christchurch Women’s Hospital (CWH) cohort consists of 67 
very/extremely premature patients who received insulin either under sliding scale-based or model-
based protocols [60]. The HINT cohort [28] was derived from detailed BG, insulin and nutrition data 
charted during the HINT trial in Auckland, NZ. This is the same cohort from which the C-peptide data 
was obtained, but those one-off weekly blood samples did not always appear in the clinical BG 
record. Of a total of 88 patients in the trial, 55 had sufficiently detailed data (BG measured at least 6 
hourly, generally more frequently) to extract one or more glycaemic episodes per subject. A 
glycaemic episode is defined as ≥ 12 hours of insulin therapy, and at least 4 BG (max 6 hours apart) 
measurements during this time. These criteria resulted in a total of 243 patient episodes across both 
cohorts, with all details in Table 3. 
SI profiles were fit to clinical data from the CWH and HINT validation cohorts using the integral 
based fitting method [60] and Equations 1-4. Ordinary differential equation solutions for Equations 1 - 
3 (G,I,Q) were generated using a Runga-Kutta 4 based method (Matlab®, ode45). Insulin kinetic 
parameter values determined in this analysis (𝑛𝐿 , 𝑛𝑘, 𝑛𝐼 , 𝑛𝑐 , 𝑉𝑃 , 𝑉𝑄) were used to generate the plasma 
and interstitial insulin concentrations (I,Q). The identified SI must remain positive to be 
physiologically correct, so the lower limit of SI was set to 1x10-7 L/mU/min (near 0, where a typical 𝑆𝐼 
is 10-4 – 10-3 L/mU/min). For comparison, SI profiles were also fit, and BG and insulin profiles 
generated, using the original NICU model [37]. Fitting and prediction error were compared between 
the older NICU model iteration and the new NICING model as a measure of validation to show 
similar performance to a working, clinically effective standard. 
 
Table 2: Clinical and sample characteristics. Numbers are presented as median [IQR] or 
number (% of total). 
Number of Patients  
 Total 41 
 Control 21 
 Tight Glycaemic Control 20 
 Male (%) 20(49%) 
Age  
 Gestational, weeks 27.2 [26.2 - 28.7] 
 Post natal, days 9.5 [4 -17] 
Birth weight  
 grams 839 [735 – 1000] 
 Z score -0.19[-1.03 - 0.14] 
 Small for gestational age 6 
Ethnicity  
 Asian 9 (22%) 
 Caucasian 11 (27%) 
 Maori 17 (41%) 
 Pacific Island 4 (10%) 
Sample results  
 Number of Samples 54 
 Day after randomisation*  7 [0 - 14] 
 BG, mmol/l 7.5 [5.1 – 10.5] 
 Plasma insulin concentration, pmol/L 59.0  [99.3 – 181.9] 
 Plasma C-peptide concentration, nmol/L 2.3 [1.1 - 4.2] 
*Samples were taken on day of randomisation 0, 7, and 14. 
 
Table 3: Patient cohort characteristics, presented as number of patients, or median [inter-
quartile range]. 
 HINT CWH 
Patients   
Total Number  55 67 
Control/TGC 33/22 22/45 
Male/female 27/28  
Age   
Gestational age, weeks 25 [24–26] 27 [25–28] 
Post natal age, days 4 [3–8] 2 [0–5] 
Birth weight   
grams 690 [740–890] 865 [690-960] 
Z score 0.02 [-0.85–0.58] -0.67 [-1.2–0.27] 
SGA 9 13 
Total Episodes 160 83 
Control/TGC 57/103 25/48 
Total hours 4673 8455 
Total BG measurements 1389 2951 
Median time between measurements 
(hours) [IQR] 
4.0 [3.5–4.8] 3.3 [2.8–3.9] 
Median BG [mmol/L] 7.10 [4.90–9.40] 7.10 [5.70–9.00]  
Median insulin rate [IQR] (U/kg/hr): 0.060 [0.033–0.080] 0.036 [0.026–0.051] 
 
2.4.3 Fitting and Prediction Error 
Fitting error was calculated as the percentage difference between the model solution at a measurement 
time and the actual measured value. Where fitting error is high, the model fails to fit clinical data and 
is therefore inappropriate. However, for appropriately constructed model dynamics, fitting error 
saturates at some lower value as the fitted insulin sensitivity ensures model fit over a reasonable range 
of parameter values [60].  For this reason, prediction error is also analysed. 
Prediction error is calculated as the percentage difference between the actual measured BG and a 1 
hour forward prediction, where 1 hour is the minimum resolution of SI in this framework. The 
prediction from time tn to tn+1 is based on SI from tn-1 to tn and the 50th percentile (median likely 
outcome) of observed outcomes based on statistical models of a base population [61]. Lower 
prediction error indicates that dynamics previously reflected in SI are now more comprehensively 
modelled. As a result, there is improved ability of the model to forward predict median likely changes 
in BG for a given insulin-nutrition treatment, which is essential for accurately assessing future patient-
specific state, and thus for effective control.  
3.0 Results 
3.1 Fluid Volume Analysis 
A total of 10 studies (n = 18 – 32, exception [62] with n = 5) examined typical fluid volumes in 
preterm neonates with an average study cohort gestation age <33 weeks and birth weight <2kg. Of 
these, 7 reported ECV values [62-67] and 4 reported VP [62, 68-70]. Figure 1 shows a significant drop 
in ECV over the first 1-2 weeks post natal age (PNA), followed by a relative plateau. Although a lot 
of variability is seen between study mean values, most studies fall within one standard deviation of 
each other.  
Given this data, a power law function (R2 = 0.44) was fit to capture the rapid decrease in ECV over 
the first few days and subsequent ECV plateau: 
𝐸𝐶𝑉 = 492 × 𝑃𝑁𝐴−0.09 (17) 
Figure 2 shows that plasma volume does not significantly change over the first couple of weeks of 
life. While Ussher and Lind [70] show a very slight decrease over time (R2 = 0.04), Bauer et al [62] 
shows a slight increase. Therefore, VP could be assumed to remain essentially constant over time, with 
an average volume of 47 mL/kg. The interstitial fluid volume is thus: 
𝑉𝑄 = 492 × 𝑃𝑁𝐴
−0.09 −   𝑉𝑃 (18) 
 
 
Figure 1: Decrease of ECV with postnatal age. Vertical Error bars are 1 standard deviation; 
horizontal error bars cover the range of days. For the Modi et al data, the median and range is 
plotted. 
 
Figure 2: Plasma (♦) and blood volume (■) changes over time. Data used is patients with 
BW<2KG from Ussher et al [70].  
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3.2 Inference of Insulin Clearance Parameters 
The results from the evaluation of Equations 14-18, using C-peptide data to estimate insulin secretion, 
are presented in Table 4 and Figure 3. It should be noted that nC is scaled by the ratio of plasma 
volume to interstitial volume, as per Equation 17. The parameter nK is made patient specific and 
dependant on a birth weight and postnatal age dependant model of GFR, according to Equations 19-
20.  The distribution of patient specific values for liver clearance, nL, calculated using Equation 18, is 
shown in Figure 3, with a median clearance of 0.39 min-1.  
Sensitivity to assumptions around diffusion between compartments and hepatic insulin clearance was 
tested and results are shown in Figure 4. As nI is an order of magnitude smaller than nL, changes in nI 
had very little effect on patient specific results for nL. Figure 4 shows that within the sensitivity range, 
nI had little effect on modelled plasma insulin concentrations. Model fit error was not affected, as the 
small change in peripheral insulin concentration, Q, resulted in a scale offset in SI. The hepatic insulin 
clearance parameter, nL, is much more sensitive, as evidenced in Figure 4 b). This aligns with 
expectations from Figure 3, where liver clearance was observed to be highly patient specific. 
Table 4: Clearance Parameters based on HINT C-peptide analysis and physiological ranges in 
adult subjects. Unless otherwise state, results are presented as Median [IQR] 
Parameter Value [1/min] 
Physiological range 
for adults [Lotz] 
Median (Range) [71] 
nI 0.025 
0.28 [0.22-0.36] [L/min] 
0.0052 [0.0041 – 0.0119] 
[1/min]* 
nK 
0.034 
[0.030-0.039] 
0.06 (0.053-0.064) 
nL 
0.39 
[0.15-0.70] 
0.15 (0.1-0.21) 
𝑛𝑐
𝑉𝑄
𝑉𝑃
= 𝑛𝐼 (
𝐼𝑠𝑠
𝑄𝑠𝑠
− 1) 0.025 - 
  * From [72] 
 
 
Figure 3: Liver clearance parameter, 𝒏𝑳, distribution derived from HINT data. 
 
Figure 4: Sensitivity analysis of on a) diffusion of insulin between compartments (𝒏𝑰), and b) 
hepatic insulin clearance 𝒏𝑳. Increasing 𝒏𝑰 was achieved by multiplying the mass ratio of 
Equation 12 by a power of [1/1, 1/1.5, 1/2, 1/2.5, 1/3], giving 𝒏𝑰 in the range 0.025 – 0.038 
1/min. 𝒏𝑳 was varied across the range: [0.20:0.10:1] 1/min. 
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Table 5 presents the fitting and prediction error results over the HINT and CWH patient cohorts for 
both the new NICING and the previous NICU [45] models. There was no difference in fitting error 
between the two models in the CWH cohort, and prediction error was slightly increased. In the HINT 
cohort, both fitting and prediction error were slightly decreased with the NICING model. All changes 
were very small relative to typical measurement errors. Figure 5 shows two examples fits to clinical 
data. Model fit is good, with only a very small undershoot on some peaks. 
 
Table 5: Fitting and Prediction error for the NICING and NICU models 
 CWH Cohort HINT Cohort 
NICING model   
Fitting Error 2.1% 2.7% 
Prediction Error 12.6 [5.2-24.7] % 18.3 [7.3-34.0] % 
NICU model   
Fitting Error 2.1% 2.9% 
Prediction Error 11.7 [5.1-23.5] % 18.8 [8.1-37.0] % 
   
 
 
 
Figure 5: Model fit in A: a very stable shorter-stay patient, and B: long-stay dynamic patient. 
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4.0 Discussion 
This study presents a more physiologically descriptive glucose-insulin model for the purposes of 
glycaemic control in premature infants. In particular, it focuses on the kinetics of insulin, which are 
necessary to obtain accurate estimates of patient-specific metabolic state, and thus accurate control. 
Previously in the NICU model [45], insulin clearance via the liver, kidney, and receptor-bound 
degradation was modelled by a single clearance parameter determined from literature data and 
minimisation of model fitting error. The NICING model separates out these clearances, adding a 
degradation term to the interstitial compartment, saturable liver clearance, and kidney clearance [38]. 
Birth weight and age based modelling of plasma volumes and GFR allow inter-compartment transport 
and renal clearances to be-patient appropriate.  
After these changes, the full NICING model system has similar or better ability to fit two cohorts of 
clinical data when compared to a simpler and less physiologically relevant previous iteration of the 
model, as evidenced by the unchanged fitting error in the CWH cohort and the reduction in the HINT 
cohort. This reflects the model’s ability to capture time-varying dynamics in the wider HINT cohort 
from which the insulin clearance parameters were derived, as well as in a separate, independent cohort 
to test whether the new model parameters were effective in capturing observed clinical dynamics. 
Prediction error was increased by ~1% in the CWH cohort, and decreased by ~1% in the HINT 
cohort, suggesting that the NICING model overall is likely to perform in a very similar manner to the 
NICU model. Clinical results to date using the old NICU model in model-based control [73, 74] 
suggest that it is robust, safe, and effective for use in glycaemic control in a NICU setting [74-76]. 
The NICING model is used in a risk-based decision framework [74, 77]. Hourly identification of SI 
allows changes in insulin sensitivity to be observed. Stochastic modelling is used to predict future 
changes in insulin sensitivity, resulting in a distribution of likely BG outcomes for a given 
intervention. Insulin interventions are chosen such that this range of likely BG outcomes overlaps 
with the desired clinical targets.  Specifically, we set a maximum risk threshold for mild 
hypoglycaemia (BG<4.0 mmol/L) at 5%. New results to date using the NICING model show further 
significant improvement in control and safety [73] over the previous NICU model, indicating that the 
new model more accurately captures underlying dynamics, beyond what can be evaluated using fitting 
and prediction error.  
Most of the insulin clearance parameters lie within the reported physiological range for adults, 
suggesting these volume normalised values are reasonable. Insulin diffusion between the plasma and 
peripheral compartments, 𝑛𝐼, is an order of magnitude faster than the adult ICING model (𝑛𝐼 =
0.003 min−1). The associated half life of action for 𝑛𝐼 is ~150 minutes, and when 𝑛𝐶 is also 
considered, the combined time to half maximal interstitial insulin for an IV insulin infusion is ~70 
minutes, which is similar to results from studies in lean and obese adults (46 and 72 minutes 
respectively) [56]. Given that that the ICING model value for 𝑛𝐼 was chosen based on extensive grid 
search and fitting error minimisation [5], it is likely that the NICING value is more physiologically 
real.  
Insulin kinetic parameters were assumed to be independent of nutritional intake. Previous work saw 
no clear trend or effect of nutrition on insulin secretion [49, 50], which is known in adults to be more 
directly affected by nutritional intake and resulting hormone signalling. 
Hepatic liver clearance was found to be highly patient specific (Figure 3), and 2-3 times higher than 
adult values [71]. The wide range of clearance values found are a reflection of the model’s sensitivity 
to this parameter (Figure 4), where, having calculated all other parameters, 𝑛𝐿 was fit such that the 
model fit the samples plasma insulin concentration. This variability could also result from 
accumulated patient-specific deviation from other model parameters, however given kidney clearance 
(𝑛𝐾) and diffusion between compartments (𝑛𝐼) are an order of magnitude smaller, this effect is not 
likely to be significant. The high variability in the results is similar to the large variability in 
endogenous glucose production seen in previous work [39], and likely a reflection of patient condition 
and metabolic maturity in this very premature cohort. Patient-specific deviations in hepatic insulin 
clearances may thus result in a bias in the overall SI profile for some patients, but are not likely to 
affect short-term changes in SI.  
The higher liver clearance constant in this premature infant cohort could be a reflection of overall 
higher hepatic metabolism and/or the relatively larger proportional mass of the infant liver. However, 
this is speculative as no studies specifically examine hepatic insulin kinetics in the premature infant. 
Premature infants have larger proportional organ mass and higher basal metabolic rate in proportion 
to total body mass than adults [78]. Previous reviews of literature show that endogenous glucose 
production (EGP) is generally higher in premature infants (median 2.2 mg/kg/min [39] vs. mean ~ 1.4 
mg/kg/min in unfasted adults [79], EGP is higher at ~ 4 mg/kg/min in fasted adults [79]) and is also 
unsuppressed at higher BG and/or glucose infusion rate in premature infants [80]. Infants born less 
than 27 weeks gestation lack glycogen stores, so intravenous/frequent exogenous nutrition is required 
to meet energy needs. Thus, the premature liver may utilise and eventually clear more insulin than its 
adult counterpart, and for this reason liver clearance of insulin may be higher. 
Birth weight and age based modelling of plasma volumes and GFR allow inter-compartment transport 
and renal clearances to be patient-appropriate. This approach is in contrast to the adult case, where 
these volumes are held constant. In addition, during the first week of life there is significant weight 
loss in the premature infant as the extracellular fluid compartment contracts. Modelling this 
contraction will prevent long term bias in identified SI profiles, thus providing more accurate SI 
estimates for use in glycaemic control.  
Insulin degradation is being modelled as a process that is unsaturated at high insulin concentrations. 
[42] observed insulin mediated glucose uptake was not saturated with insulin concentration. Insulin 
mediated glucose uptake is a receptor-mediated process, and receptor-bound insulin is either released 
back into the extracellular space, or internalised by the cell [43]. As such, the same saturation 
parameter is applied to both insulin-mediated glucose uptake and insulin degradation. In this case it 
has been set to zero, due to the lack of observed saturation of insulin-mediated glucose uptake.  
Glycaemic control using the ICING model in the adult intensive care unit has proven safe and 
effective, with low incidence of hypoglycaemia and around 90% time in a clinically targeted range of 
4.0-8.0mmol/L [3]. The NICING model is based on the ICING model, and should thus allow 
consistency with existing adult ICU glycaemic control protocols and T1DM/T2DM orientated models 
[81]. The greater physiological descriptiveness of the NICING model in comparison to the old NICU 
model additionally allows it to be more easily customised to the infant case using clinical C-peptide 
data, when available, and future metabolic studies.  
Study limitations include the assumption of steady state kinetics in the analysis of C-peptide 
concentrations. Due to the inherent extreme fragility of this premature neonatal cohort, serial blood 
samples are not practically or ethically possible, so the more detailed model based analysis of C-
peptide and insulin kinetics seen in adult studies [48, 82] are not possible. Such steady-state 
assumptions are not unreasonable in this cohort, as the majority of nutrition is given via parenteral 
infusion, or enteral feeds, which do not tend to change dramatically from hour to hour. In addition, 
none of the samples were taken within 2 hours of an infant starting insulin infusion. Hence, the 
assumption of steady state conditions is both reasonable and a necessity in this cohort.  
Further, no kinetic parameters are available for C-peptide dynamics specific to this cohort, so adult 
kinetic parameters, adjusted for age, were used. Patient specific parameters for neonates cannot be 
determined due to the demands of the procedure. While it is understandably not desirable to use age to 
extrapolate these adult parameters this far beyond the cohort for which they were originally validated, 
the resulting normalised parameter values fall within ranges reported in studies on adults [48, 51]. 
This outcome provides a level of qualitative validation that the assumption used is not poor. In 
addition, using adult kinetic population constants, particularly under the assumption of steady state, is 
not likely to change any of the underlying trends observed, and scale differences are absorbed by the 
model in an overall shift in SI without altering control outputs. Thus, as long as SI forecasting models 
are scaled consistently, relative changes in SI, enabling BG prediction, are accounted for. If this model 
were to be used in a more detail-oriented setting (e.g. like the metabolic analysis of [1, 2]), or if 
patient-specific insulin parameters (e.g. liver clearance), were to be identified in real time for control, 
this assumption may require revisiting and further examination.  This study highlights the need for 
data and studies to validate any significant differences in neonatal kinetics that would affect this 
assumption, as well as, more generally, the potential value of pursuing such studies in this cohort. 
A limitation of the HINT data used in validation is that all nutritional data was recorded as daily 
totals. It was assumed that daily totals were delivered as a constant infusion over the course of the 
day, which is not unreasonable in this cohort. However, the slightly higher fitting error in this cohort 
is likely caused in part by this assumption.  
 
5.0 Conclusions 
A physiological model of glucose-insulin kinetics for use in glycaemic control in very premature 
infants is presented. The insulin kinetics model is more physiologically descriptive than previously, 
and parameters identified using a novel set of C-peptide concentrations from very premature infants. 
Cohort and infant-specific insulin clearance parameters were identified for clearance through the liver, 
the kidneys, and peripheral degradation. Saturation of liver clearance at high insulin concentration is 
modelled, and kidney clearance is modelled according to changes in kidney function with birth weight 
and gestational age. Estimations of insulin distribution values based on fluid compartments are found 
from literature data, and the post-natal contraction of the extracellular fluid compartment is also 
captured. Fitting error between the model and clinical validation data across two clinical data sets 
indicate that this model has a similar or better ability to fit clinical data compared to a previous, less 
physiologically detailed and relevant NICU model, and tight glycaemic control performance is 
significantly improved.  
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